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Protein synthesis has long been known to be required for associative learning to consolidate into long-term memory. Here we
demonstrate that PKC isozyme activation on days before training
can induce the synthesis of proteins necessary and sufficient for
subsequent long-term memory consolidation. Bryostatin (Bryo), a
macrolide lactone with efficacy in subnanomolar concentrations
and a potential therapeutic for Alzheimer’s disease, is a potent
activator of PKC, some of whose isozymes undergo prolonged
activation after associative learning. Under normal conditions, two
training events with paired visual and vestibular stimuli cause
short-term memory of the mollusc Hermissenda that lasts ⬇7 min.
However, after 4-h exposures to Bryo (0.25 ng兾ml) on two preceding days, the same two training events produced long-term conditioning that lasted >1 week and that was not blocked by
anisomycin (1 g兾ml). Anisomycin, however, eliminated long-term
memory lasting at least 1 week after nine training events. Both the
nine training events alone and two Bryo exposures plus two
training event regimens caused comparably increased levels of the
PKC ␣-isozyme substrate calexcitin in identified type B neurons and
enhanced PKC activity in the membrane fractions. Furthermore,
Bryo increased overall protein synthesis in cultured mammalian
neurons by up to 60% for >3 days. The specific PKC antagonist
Ro-32-0432 blocked much of this Bryo-induced protein synthesis as
well as the Bryo-induced enhancement of the behavioral conditioning. Thus, Bryo-induced PKC activation produces those proteins
necessary and sufficient for long-term memory on days in advance
of the training events themselves.
bryostatin 兩 PKC isozymes

T

he requirement of protein synthesis for long-term memory
has been demonstrated over several decades for a variety of
memory paradigms (1–14). It was originally shown that druginduced inhibition of protein synthesis (e.g., with 5-propyluracil
or anisomycin) blocked long-term memory when this inhibition
occurred during a critical time interval after the training paradigm (9). It has remained a mystery as to what specific, critical
proteins were so essential for memory consolidation and how
their molecular regulation was so necessary for long-lasting
memory storage.
In many species the formation of long-term associative memory has also been shown to depend on translocation, and thus
activation, of protein kinase C (PKC) isozymes to neuronal
membranes. PKC activation has been shown to occur in single
identified type B cells of the mollusc Hermissenda (15) with
Pavlovian conditioning and a variety of mammalian associative
learning protocols (16–18). Furthermore, a high-affinity substrate of the ␣-isozyme of PKC, calexcitin (CE) (19), was found
within single identified type B cells to show Pavlovianconditioning-dependent increases of phosphorylation and absolute quantity (20).
Consistent with these findings, administration of the potent
PKC activator bryostatin (Bryo) enhanced rat spatial maze
learning (21). Bryo, a macrolide lactone, has efficacy in sub16432–16437 兩 PNAS 兩 November 8, 2005 兩 vol. 102 兩 no. 45

nanomolar concentrations (22–24). Like phorbol esters and the
endogenous activator diacylglycerol, Bryo binds to the C1 domain within PKC and causes its translocation to membranes,
which is then followed by down-regulation (25, 26). However,
unlike most other identified exogenous PKC activators, Bryo is
not tumorigenic, but instead shows anti-neoplastic properties
and has been investigated in cancer clinical trials (22, 27).
Here, we hypothesized that periods of drug-induced PKC
activation on days before initiation of training might have
long-lasting impact on memory consolidation, perhaps through
PKC-dependent synthesis of those proteins critically required for
long-term memory. Sufficient PKC activation and prior PKCmediated synthesis of critical proteins might reduce the number
of training events (TEs) required and eliminate the requirement
for further protein synthesis to produce long-term memory. The
report described here confirms these predictions and supports
the hypothesis that PKC activation on days preceding training
induces protein synthesis necessary and sufficient for consolidation of long-term memory.
Materials and Methods
Behavioral Conditioning. Pavlovian conditioning of Hermissenda

involves repeated pairings of a neutral stimulus, light, with an
unconditioned stimulus, orbital shaking [see Lederhendler et al.
(28) and Epstein et al. (29)]. A rotation兾shaking stimulus excites
the statocyst hair cells and thereby elicits an unconditioned
response: a brisk contraction of the muscular undersurface
called a foot, accompanied by adherence or ‘‘clinging’’ to the
surface that supports the foot. Before conditioning, light elicits
a weakly positive phototaxis accompanied by lengthening of the
foot. After sufficient light–rotation pairings, light no longer
elicits phototaxis but instead elicits a new response (28): the
‘‘clinging’’ and foot shortening previously elicited only by the
unconditional stimulus (see Fig. 1). This conditioned response to
light can last for weeks, is not produced by randomized light and
rotation, is stimulus-specific, and shares the other defining
characteristics of mammalian Pavlovian conditioning.
Graphs in the figures shown below depict behavioral changes
in terms of percentage of length change. However, graphic
representations of all behavioral effects were virtually identical,
producing the same statistically significant differences, when
using percentage of change of foot length or using the actual
length measurements acquired from video camera recordings.
For example, in Fig. 4, at 96 h, the length increment responses
in trained animals preexposed to Bryo were ⫺0.50 and ⫺0.52
mm. These points correspond to ⫺2.6% and ⫺2.9% change,
respectively.
Long-term Pavlovian conditioning of Hermissenda usually
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reverses after 1–2 weeks. This reversal, demonstrated in many
previous articles, is, for the most part, not illustrated in the
figures presented here.

Immunostaining Methods. CNSs were removed and fixed in 4%
paraformaldehyde in 20 mM Tris-buffered (pH 8) natural seawater (0.2-m micropore-filtered), embedded in polyester wax
(20), sectioned (6 m) and immunostained by using a biotinylated secondary antibody coupled to avidin-bound microperoxidase (ABC method, Vector Laboratories). Aminoethylcarbazole was used as the chromogen. The primary polyclonal
antibody (designated 25U2) was raised in rabbits from the
full-length CE protein extracted from squid optic lobes. Grayscale intensity measures were done from digital photomicrographs by using IMAGE-J software on circumscribed cytoplasmic
areas of the B-photoreceptors minus the same background area
(nonstaining neuropile).
Biochemistry. PKC assay. Cells were homogenized by sonication (5

sec, 25 W) in 100 l of 10 mM Tris-HCl (pH 7.4) buffer
containing 1 mM EGTA, 1 mM PMSF, and 50 mM NaF.
Homogenate was transferred to a polyallomer centrifuge tube
and was centrifuged at 100,000 ⫻ g for 10 min at 4°C. The
supernatant was removed and immediately frozen on dry ice.
The particulate fraction was resuspended by sonication in 100
l of the same buffer and stored at ⫺80°C. To measure PKC,
10 l of cytosol or particulate fraction was incubated for 15
min at 37°C in the presence of 10 M histones, 4.89 mM CaCl2,
1.2 g兾l phosphatidyl-L-serine, 0.18 g兾l 1,2-dioctanoyl-snglycerol, 10 mM MgCl2, 20 mM Hepes (pH 7.4), 0.8 mM
EDTA, 4 mM EGTA, 4% glycerol, 8 g兾ml aprotinin, 8 g兾ml
leupeptin, and 2 mM benzamidine. [␥-32P]ATP (0.5 Ci) was
added, and 32P-phosphoprotein formation was measured by
adsorption onto phosphocellulose as described previously
(31). This assay, used with slight adjustments for either
Hermissenda nervous system homogenates or cultured mammalian neuron homogenates, measures the calcium and diacylglycerol-dependent phosphorylation of histones by protein
kinase. Other protein kinases that act on histones and are
dependent on calcium and diacylglycerol potentially could also
be measured by this assay. However, protein kinase D (formerly known as PKC) also binds diacylglycerol, but it is not
calcium-dependent (32). Other major kinases, such as Ca2⫹兾
calmodulin kinase II, protein kinase A, casein kinase, mitogenactivated protein kinases, and tyrosine kinases, would not be
detected in our assay.
Cell culture. Rat hippocampal H19-7兾IGF-IR cells (American
Type Culture Collection) were plated onto poly-L-lysine-coated
Alkon et al.

Fig. 1. Effect of Bryo on long-term retention. Animals were trained with four
and six paired conditioned stimulus兾unconditioned stimulus TEs with Bryo
(0.25 ng兾ml). Bryo was added during dark adaptation (10 min) before training
and continued for 4 h. All animals were tested with the conditioned stimulus
alone at 4 h, then at 24-h intervals after training. Animals trained suboptimally
but treated with Bryo all demonstrated long-term retention (n ⫽ 8 –16,
ANOVA, P ⬍ 0.01). Filled squares (dashed lines) are displaced slightly to the
right for clarity. Lowest dashed line indicates previously observed effect of
nine training trials.

plates and grown at 35°C in DMEM兾10% FCS for several days
until ⬇50% coverage was obtained. The cells were then induced
to differentiate into a neuronal phenotype by replacing the
medium with 5 ml of N2 medium containing 10 ng兾ml basic
fibroblast growth factor at 39°C and grown in six-well plates (33).
Various concentrations of Bryo (0.01–1.0 nM) were then added
in 10 l of aqueous solution. After a specified interval the
medium was removed and the cells were washed with PBS,
removed by gentle scraping, and collected by centrifugation at
1,000 rpm for 5 min.
Results
Bryo-Induced Prolongation of Associative Memory. Two TEs of

paired light and orbital shaking (see Materials and Methods)
induce a learned, Pavlovian-conditioned response (light-elicited
foot contraction or shortening) that persists without drug treatment for ⬇7 min. Four to six TEs induce a conditioned response
that persists up to a few hours, whereas nine TEs produce
long-term associative memory lasting as long as 2 weeks (Fig. 1
Lower, dotted line). However, two TEs plus Bryo produced
memory retention lasting hours (vs. minutes without Bryo), four
TEs plus Bryo extended retention beyond 24 h (Fig. 1), and six
TEs plus Bryo produced retention lasting 1 week or longer.
Randomized presentations of light and rotation, with or without

Fig. 2. Effects of blockers on retention. (A) Four-hour retention effects of
Bryo under control and antagonist experimental regimes (NSW, normal sea
water controls). R032, Ro-32-0432 blocks retention with six TE plus Bryo. (n ⫽
4 – 8; ANOVA, P ⬍ 0.01.) (B) Effects of Bryo and anisomycin on retention after
4 h. Animals received two paired TEs in normal sea water (NSW), 0.25 ng兾ml
Bryo, or 0.25 ng兾ml Bryo plus 1 ng兾ml anisomycin. (n ⫽ 12, each group;
two-way ANOVA, P ⬍ 0.01.)
PNAS 兩 November 8, 2005 兩 vol. 102 兩 no. 45 兩 16433
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Behavioral Pharmacology: Bryo Exposure. Specimens of Hermissenda crassicornis were purchased from Sea Life Supply (Sand
City, CA) and maintained in artificial sea water (ASW) at 15°C
for 3 days in perforated 50-ml conical centrifuge tubes before
starting experiments. Bryo (Calbiochem), purified from the
marine Bryozoan Bugula neritina, was dissolved in ethanol and
diluted to its final concentration in ASW. Animals were incubated with Bryo in ASW for 4 h, then rinsed with normal ASW.
For selected experiments lactacystin (10 M) or anisomycin was
added to the ASW. Bryo is stable for at least 28 days at room
temperature in saline solutions at neutral pH with no measurable
decomposition, provided that exposure to UV light is minimized
(30). Bryo effects on Hermissenda behavior were produced by
adding the drug to the bathing medium within an 8-cm-long,
1-cm-diameter test tube housing each individual animal. For
effects on PKC activity, Hermissenda were exposed to Bryo in
their individual 50-ml conical centrifuge tubes, thereby eliminating possible effects caused by transferring the animals to
separate containers.

Fig. 3. Effect of two successive days of 4-h Bryo exposure (0.25 ng兾ml)
followed 1 day later by two TEs. Retention was measured up to 144 h after
training. (n ⫽ 16; ANOVA, P ⬍ 0.01.)

Bryo, produced no conditioned response (Fig. 2A), i.e., lightelicited foot contraction.
Preexposure to Bryo on Days Before Training Enhances Memory
Retention. A 4-h exposure to Bryo on the day before training as well

as on the day of training, followed by two TEs, prolonged memory
retention to ⬎24 h after training. Two successive days of 4-h Bryo
exposures followed on the subsequent day by two TEs alone
produced long-term memory lasting at least 6 days (Fig. 3). A third
day of exposure to the 4-h Bryo treatment caused a similar
enhanced retention of the Pavlovian-conditioned response (Fig. 4).
A single more prolonged Bryo exposure, i.e., for 8–20 h, followed
by two TEs was not sufficient itself to produce memory retention
equivalent to that accompanied the two 4-h exposures on successive
preceding days. Sufficiently prolonged Bryo exposure (e.g., 8–12 h)
is known in other cell systems to cause prolonged PKC downregulation. Similarly, sufficiently increased concentrations of Bryo
ultimately blocked memory retention (Fig. 5) presumably also
because of PKC down-regulation.

Fig. 5. Dose–response curves for four and nine paired conditioned stimulus兾
unconditioned stimulus TEs. Bryo concentrations ⬍0.50 ng兾ml augmented
acquisition and memory retention with suboptimal (four TE) training conditions. Those concentrations had no demonstrable effects on retention performance with nine paired TEs. However, with all training conditions tested,
Bryo ⱖ1.0 ng兾ml inhibited acquisition and behavioral retention (n ⫽ 16).
Retention of four paired TE conditioning with 20-h preexposure to Bryo
persisted for 24 h (n ⫽ 8; ANOVA at 48 h, P ⬍ 0.01).

Preexposure to Bryo Obviates the Requirement for Protein Synthesis
During Training. A single 4-h exposure to Bryo together with two

TEs produced long-term memory retention lasting several hours
that was entirely eliminated when anisomycin was present along
with the Bryo (Fig. 2B). Similar blocking effects of anisomycin
on long-term memory were also observed with six TEs plus Bryo
or nine TEs alone (27). However, when we blocked protein
synthesis for 4 h with anisomycin immediately after two TEs for
animals that on each of three preceding days had been first
exposed to 4 h of Bryo, anisomycin did not prevent memory
retention that lasted at least 4 days (Fig. 4). Finally, if two TEs
were given 1 day after three successive days of 4-h exposures to
Bryo that was accompanied each time by anisomycin, long-term
memory was eliminated.
Preexposure to Proteasome Inhibition Enhances Bryo Effects on
Memory. The ubiquitin–proteasome pathway (34, 35) is known to

be a major route for degradation of the ␣-isozyme of PKC.
Therefore, to prolong PKC activation, we added lactacystin (10
M), a known proteasome inhibitor (34, 35), during a single 4-h
exposure to Bryo followed 24 h later by two TEs. Lactacystin, in
this case, transformed the short-term memory produced by the
single Bryo exposure (followed by two TEs) to long-term
memory lasting 4 days (Fig. 6).
Immunohistochemistry: CE Immunostaining After PKC Activation. CE,

Fig. 4. Effect of three successive days of 4-h Bryo exposure (0.25 ng兾ml)
followed 1 day later by two TEs. Retention was measured over 96 h after
training. Nonexposed animals (same as in Fig. 3) did not demonstrate any
behavioral modification (no conditioned response to conditioned stimulus
testing) (Upper). Anisomycin (1 g兾ml) administered immediately and remaining for 4 h after training to animals receiving the 3-day Bryo treatments did
not prevent long-term retention (Lower). (n ⫽ 16; ANOVA, P ⬍ 0.01.) Note that
the control data (Upper) are the same as in Fig. 3.
16434 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0508001102

a low-molecular-weight calcium and GTP-binding protein and
a high-affinity substrate for the ␣-PKC isozyme, is phosphorylated during Hermissenda conditioning (19) and increases
within single identified type B cells (20). The intensity of CE
immunostaining (Figs. 7 and 8A) increased within the type B
cells with the number of TEs, reached a plateau (four to five
times baseline) of 60 –70 units (see Materials and Methods) with
nine TEs (sufficient to induce memory retention lasting
several days), and was prevented by the specific PKC blocker
Ro-32-0432. This conditioning-induced CE label increase represents an increase in the actual amount of the protein because
the immunostaining antibody reacts with both the phosphorylated and unphosphorylated forms of the protein. Twentyfour hours after two Bryo exposures on each of two successive
days, there was greater residual CE immunostaining, and even
greater CE levels after three successive days of Bryo exposure.
Alkon et al.

With two TEs on the day after these three exposures, CE
immunostaining 24 h later approached the levels previously
observed immediately after nine TEs (Fig. 8B). Finally, this

Fig. 7. Representative tissue sections from Hermissenda eyes immunolabeled with CE antibody. (A) Random presentations of the two stimuli (TEs) did
not produce behavioral modifications or a rise in CE above normal background levels. Basement membrane and lens staining are artifacts associated
with using vertebrate polyclonal antibodies. (B) Positive CE immunostaining
occurred in B cell photoreceptors (*B-Cell) of trained animals (two TEs) after
2 days’ Bryo exposure intervals. (C) Intensity measures after nine random TEs
or two exposures on successive days to Bryo (0.25 ng兾ml), and then associatively followed by two paired TEs. Two exposures of Bryo coupled with two TEs
significantly increased CE to levels associated with nine paired TEs and consolidated (long-term) memory (n ⫽ 4 – 8; t test, P ⬍ 0.01). CE immunostaining
also resolved boutons within synaptic fields of photic-vestibular neurites (D).
Arrows indicate arborization field between an interneuron (a), axon from a
contralateral neuron (b), and terminal boutons of neurites from a putative
photoreceptor (c). (Scale bars, 10 m.) CPG, cerebropleural ganglion.

Alkon et al.

CE immunostaining was not reduced when anisomycin followed two TEs preceded by 3 days of 4-h Bryo exposures (n ⫽
8 animals with and 8 animals without anisomycin, t test, P ⬎
0.5, not statistically significant).
Biochemistry. Bryo is known to transiently activate PKC by
increasing PKC association with the cellular membrane fraction.
In addition, Bryo exposures (4 h each) on two successive days
were followed 24 h later by increased PKC activity in both the
membrane and cytosol fractions (Fig. 9). Consistent with an
increased synthesis of PKC as well as PKC activation, the
presence of anisomycin during each of three successive days of
Bryo completely eliminated PKC increases (n ⫽ 9, P ⬍ 0.01) as
well as the subsequent memory consolidation produced by two
TEs.
To further examine biochemical consequences of repeated
exposures to Bryo, we used rat hippocampal neurons that had
been immortalized by retroviral transduction of temperaturesensitive tsA58 SV40 large T antigen (31). These differentiate
to a neuronal phenotype when induced by basic fibroblast
growth factor in N2 medium (33) and express a normal
complement of neuronal proteins, including PKC. Exposure
of cultured hippocampal neurons to a single activating dose of
Bryo (0.28 nM) for 30 min produced a brief translocation of
PKC from the cytosol to the particulate fraction (evidenced by
a 60% increase in activity in the membrane fraction) followed

Fig. 9.
PKC activity in Hermissenda nervous systems after Bryo. Intact
Hermissenda were exposed for 4-h intervals to Bryo (0.28 nM) on successive
days as described in the text. PKC activity in isolated circumesophageal nervous systems was then measured in the cytosol fraction. (Left) Cytosol. (Right)
Particulate fraction. (n ⫽ 6 –12 for each measurement; *, P ⬍ 0.05; **, P ⬍ 0.01,
two-tailed t test).
PNAS 兩 November 8, 2005 兩 vol. 102 兩 no. 45 兩 16435
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Fig. 6. Behavioral effects of Bryo and lactacystin. Animals were incubated
simultaneously for 4 h with Bryo (0.25 ng兾ml) with and without lactacystin (10
M), and then 24 h later were conditioned with two paired conditioned stimulus兾
unconditioned stimulus TEs. Animals were subsequently tested with the conditioned stimulus alone at 4 h after training and then at 24-h intervals (n ⫽ 28,
combined Bryo兾lactacystin; n ⫽ 20, Bryo alone; n ⫽ 16, lactacystin alone).

Fig. 8. Effects of Bryo and training on CE immunostaining. (A) Immunointensity measurements (0 –255) of CE antibody labeling. CE levels (0 –255 relative units) increased ⬎4.3 times with paired training (mean ⫾ SE, n ⫽ 5 animals
per treatment). 4RanTE, random control, four trials with random light and
rotation; 6PTE, paired trials, six trials with paired light and rotation. 6PTE-0Bry
vs. 6PTE-0.25Bry: P ⬍ 0.001; 4RTE-0.25Bry vs. 6PTE-0.25Bry: P ⬍ 0.001 (t test).
(B) Effect of Bryo alone (without associative conditioning) administered for
4-h over each of 1, 2, and 3 days with and without two TEs on CE levels in the
B photoreceptors of Hermissenda 24 h after each of the periods of Bryo
exposures. (n ⫽ 16; ANOVA, P ⬍ 0.01.)

Fig. 10. Effect of Bryo on membrane-bound PKC activity in hippocampal
cultured IGF-IR cells after a single 30-min exposure (Upper) or two 30-min
exposures separated by intervals of 30 min to 8 h (Lower) (n ⫽ 3– 6 for each
measurement; *, P ⬍ 0.05; **, P ⬍ 0.01, two-tailed t test). Two 30-min
exposures separated by intervals of 2 or 3 h (but not 4 h) caused PKC downregulation in the cytosol (n ⫽ 3– 6 for each group; P ⬍ 0.05 and P ⬍ 0.01,
respectively, two-tailed t test).

by a prolonged down-regulation (Fig. 10). Exposing the cultured hippocampal neurons to one 30-min period of Bryo,
followed by a second 30-min exposure, at intervals ranging
from 30 min to 8 h, caused the membrane-bound PKC to
rebound more quickly. Thus, a second exposure after a 2- to
4-h delay eliminated the significant down-regulation that a
single Bryo exposure produced (Fig. 10). In the cytoplasmic
fraction, no significant alteration of PKC activity was detected
within the first 4 h after Bryo exposure. In contrast, if cells
were exposed to Bryo twice within a 2-h period, there was a
significant reduction of PKC activity in response to the second
exposure. However, if the second exposure was delayed until
4 h after the first, activity was increased above baseline to a
degree that was significantly greater compared with a second
exposure delivered after 2 h or less (see Fig. 10 legend). These
results are consistent with the interpretation that the initial
Bryo activation of PKC followed by down-regulation (34 –36)
leads to increased synthesis (via de novo protein synthesis) of
PKC isozymes (as well as CE, described earlier). In fact, we
found here that a single 30-min exposure to 0.28 nM Bryo
increased overall protein synthesis (Fig. 11), measured by
incorporation of [35S]methionine in the last half-hour before
collecting the neurons, by 20% within 24 h, increasing to 60%
by 79 h after the Bryo exposure, but increasing significantly
less in the presence of the PKC inhibitor Ro-32-0432. (Fig. 11).
Discussion
The nontumorigenic PKC activator Bryo has undergone extensive testing in humans for the treatment of cancer in doses (20
g兾m2 to 120 g兾m2 per week) known to cause initial PKC
activation followed by prolonged down-regulation (34–36).
Phorbol esters and Bryo compete with diacylglycerol at the C1
domain of PKC. Other diacylglycerol-binding proteins containing closely related C1 domains, such as RasGRP (37, 38), and
other C1 domain-containing proteins that bind phorbol esters
such as chimaerins and munc13 (39, 40) are also potential targets
for Bryo. Bryo has also recently been shown to activate the
␣-secretase (secondary to PKC activation) that cleaves the
amyloid precursor protein (APP) to generate the nontoxic
fragment soluble precursor protein sAPP from human fibroblasts (41). Bryo also enhances learning and memory retention
of the rat spatial maze task (21), learning of the rabbit nictitating
membrane paradigm (B. Schreurs and D.L.A., unpublished
16436 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0508001102

Fig. 11. Effect of Bryo on protein synthesis. (Upper) Rat IGF-IR cells were
incubated for 30 min with 0.28 nM Bryo for incubation times ranging from 1
to 79 h. [35S]Methionine (9.1 Ci) was then added to the medium followed by
analysis of radiolabel as described in Materials and Methods. (Lower) Rat
IGF-IR cells were incubated as above in the presence or absence of 100 nM
Ro-32-0432. (n ⫽ 6 for each measurement; *, P ⬍ 0.05; **, P ⬍ 0.01, two-tailed
t test.)

data), and, in a preliminary report, Hermissenda conditioning.§
Here, Bryo in low doses (0.1–0.25 ng兾ml) markedly enhanced
memory after two, four, or six TEs. Pavlovian conditioning with
two TEs was prolonged from 7 min to several hours by Bryo, and
with six TEs from hours to many days with Bryo. This memory
enhancement was blocked by anisomycin or the PKC inhibitor
Ro-32-0432. Bryo also increased the synthesis of CE (19, 42)
within type B cells as occurs with Pavlovian conditioning of
Hermissenda, both increases blocked by Ro-32-0432. Thus, Bryo,
in lower doses (0.1–0.25 ng兾ml), and with limited intervals of
exposure, initially enhances PKC activation followed at first by
down-regulation and then prolonged (days) enhancement of
protein synthesis. Furthermore, Bryo-induced enhancement of
protein synthesis apparently enhances the duration of the memory of Pavlovian-conditioned responses. Consistent with these
findings, Bryo-induced PKC activation on days before training is
sufficient, with minimal training trials, to cause long-term memory. This latter long-term memory does not require protein
synthesis after the training (after PKC activation on preceding
days). One of those proteins whose synthesis is induced by
Bryo-induced PKC activation as well as conditioning trials is CE,
as demonstrated by the immunostaining labeling. It is also
possible that synthesis of PKC itself might also be increased (see
Fig. 9). PKC, after activation induced by Bryo, has been shown
to be down-regulated by two distinct pathways, one proteasomemediated and the other mediated by the phosphatases PP1 and
PP2A (31). With sufficient concentrations and兾or durations of
PKC activators, the PKC-degrading pathways create a deficit of
PKC that is offset by de novo synthesis of PKC. With sufficient
activation, however, PKC synthesis cannot compensate for inactivation and down-regulation, thereby causing depletion of
available PKC of 95% or more, thereby explaining inhibition of
Hermissenda learning with higher Bryo concentrations.
§Scioletti,

A. B., Kuzirian, A. M., Epstein, H. T., Nelson, T. J. & Alkon, D. L. (2004) Biol. Bull.
207, 159 (abstr.).
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learning to produce long-term memory. Apparently, PKC
activation itself, independent of training, induces the synthesis
of those proteins (e.g., calexcitin) that are necessary and
sufficient to produce long-term memory after training. Those
proteins whose synthesis is stimulated by PKC activation may
be, therefore, uniquely critical for long-term memory storage.
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NEUROSCIENCE

It is possible, therefore, that one primary requirement of
protein synthesis after associative learning in many species
may be to manufacture de novo PKC to replenish downregulated PKC. Persistence of PKC as well as other proteins
synthesized during this prior period of Bryo exposure would
then eliminate the requirement for protein synthesis after
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